RT Journal Article
SR Electronic
T1 Evidence for and level of herd immunity against SARS-CoV-2 infection: the ten-community study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.24.20200543
DO 10.1101/2020.09.24.20200543
A1 Jeremijenko, Andrew
A1 Chemaitelly, Hiam
A1 Ayoub, Houssein H.
A1 Hassan Abdulla, Moza Abdellatif
A1 Abou-Samra, Abdul-Badi
A1 Al Ajmi, Jameela Ali A.A.
A1 Al Ansari, Nasser Ali Asad
A1 Kanaani, Zaina Al
A1 Khal, Abdullatif Al
A1 Kuwari, Einas Al
A1 Al-Mohammed, Ahmed
A1 Al Molawi, Naema Hassan Abdulla
A1 Naomi, Huda Mohamad Al
A1 Butt, Adeel A.
A1 Coyle, Peter
A1 El Kahlout, Reham Awni
A1 Gillani, Imtiaz
A1 Kaleeckal, Anvar Hassan
A1 Masoodi, Naseer Ahmad
A1 Thomas, Anil George
A1 Nafady-Hego, Hanaa
A1 Latif, Ali Nizar
A1 Shaik, Riyazuddin Mohammad
A1 Younes, Nourah B M
A1 Abdul Rahim, Hanan F.
A1 Yassine, Hadi M.
A1 Al Kuwari, Mohamed G.
A1 Al Romaihi, Hamad Eid
A1 Al Thani, Sheikh Mohammad
A1 Bertollini, Roberto
A1 Abu-Raddad, Laith J.
YR 2020
UL http://medrxiv.org/content/early/2020/09/28/2020.09.24.20200543.abstract
AB Background Qatar experienced a large severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic that disproportionately affected the craft and manual workers (CMWs) who constitute 60% of the population. This study aimed to investigate level of immunity in communities within this population as well as infection exposure required to achieve herd immunity.Methods Anti-SARS-CoV-2 seropositivity was assessed in ten CMW communities between June 21 and September 9, 2020. PCR positivity, infection positivity (antibody and/or PCR positive), and infection severity rate were also estimated. Associations with anti-SARS-CoV-2 positivity were investigated using regression analyses.Results Study included 4,970 CMWs who were mostly men (95.0%) and <40 years of age (71.5%). Seropositivity ranged from 54.9% (95% CI: 50.2-59.4%) to 83.8% (95% CI: 79.1-87.7%) in the different CMW communities. Pooled mean seropositivity across all communities was 66.1% (95% CI: 61.5-70.6%). PCR positivity ranged from 0.0% to 10.5% (95% CI: 7.4-14.8%) in the different CMW communities. Pooled mean PCR positivity was 3.9% (95% CI: 1.6-6.9%). Median cycle threshold (Ct) value was 34.0 (range: 15.8-37.4)—majority (79.5%) of PCR-positive individuals had Ct value >30 indicative of earlier rather than recent infection. Infection positivity (antibody and/or PCR positive) ranged from 62.5% (95% CI: 58.3-66.7%) to 83.8% (95% CI: 79.1-87.7%) in the different CMW communities. Pooled mean infection positivity was 69.5% (95% CI: 62.8-75.9%). Only five infections were ever severe and one was ever critical—an infection severity rate of 0.2% (95% CI: 0.1-0.4%).Conclusions Based on an extended range of epidemiological measures, active infection is rare in these communities with limited if any sustainable infection transmission for clusters to occur. At least some CMW communities in Qatar have reached or nearly reached herd immunity for SARS-CoV-2 infection at a proportion of ever infection of 65-70%.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors are grateful for support provided by the Ministry of Public Health, Hamad Medical Corporation, and the Biomedical Research Program and the Biostatistics, Epidemiology, and Biomathematics Research Core, both at Weill Cornell Medicine-Qatar. The statements made herein are solely the responsibility of the authors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by Hamad Medical Corporation and Weill Cornell Medicine-Qatar Institutional Review Boards.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in an aggregate form in the main text and supplementary materials.